Asymchem Laboratories (Tianjin) Co., Ltd.
ISIN CNE100002BZ6
|WKN A2DUQX
Market cap (in EUR)
4,529 m
Country
China
Sector
Healthcare
Dividend yield
1.05%
Overview
Description
Asymchem Laboratories (Tianjin) Co., Ltd. engages in the research and development, and production of intermediates, and active pharmaceutical ingredients. Its business scopes include small molecule contract development and manufacturing organization (CDMO), and emerging service businesses. Its Small Molecule CDMO business provides process development and analysis, clinical drug production, new drug application and approval services, and current good manufacturing practice commercial production services. Its Emerging Service business covers chemical macromolecules, formulations, biosynthesis technology, biological macromolecules, and clinical research services. The company was founded by Hao Hong on October 7, 1998 and is headquartered in Tianjin, China.
Healthcare Healthcare Services Outsourced Development and Manufacturing Services China
Financials
Key metrics
| Market capitalisation, EUR | 4,529 m |
| EPS, EUR | 0.37 |
| P/B ratio | 2.1 |
| P/E ratio | 35.9 |
| Dividend yield | 1.05% |
Income statement (2024)
| Revenue, EUR | 736 m |
| Net income, EUR | 122 m |
| Profit margin | 16.57% |
What ETF is Asymchem Laboratories (Tianjin) Co., Ltd. in?
There are 15 ETFs which contain Asymchem Laboratories (Tianjin) Co., Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Asymchem Laboratories (Tianjin) Co., Ltd. is the JPMorgan China A Research Enhanced Index Equity (ESG) UCITS ETF USD (dist).
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.